Tissue Regenix Group PLC Change of Adviser (3816O)
January 31 2023 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 3816O
Tissue Regenix Group PLC
31 January 2023
Tissue Regenix Group plc
('Tissue Regenix', the 'Company' or the 'Group')
Change of Adviser
Tissue Regenix (AIM: TRX), the regenerative medical device
company, is pleased to announce the appointment of finnCap Ltd as
its Nominated Adviser and Broker with immediate effect.
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
finnCap Ltd (Nominated Adviser and Broker) Tel: +44(0)20 7220 500
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR & IR) Tel: +44(0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field
of regenerative medicine. The Company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue, leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or damaged body structures. Current
applications address many critical clinical needs in sports
medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specialises in regenerative
medicine and is dedicated to the development of high quality,
innovative tissue scaffolds, which can enhance healing
opportunities in defects created by trauma and disease.
CellRight(R)'s human tissue products may be used in spine, trauma,
general orthopaedic, dental and ophthalmological surgical
procedures.
AIM Rule 17 Disclosure
The Company announces the following additional director
disclosures pursuant to AIM Rule 17 and Schedule 2(g) of the AIM
Rules for Companies.
David Cocke
Regarding the directorship disclosures made in David Cocke's
announcement of appointment on 21 January 2021, Packaging Partners
LC and NuPak Medical Ltd were announced as previous directorships
(within the previous 5 years) when they were current directorships.
In addition, David Cocke had been a partner of Talon Medical Ltd
within the previous 5 years of his appointment to the Board of
Tissue Regenix.
Jonathan Glenn
Regarding the disclosures made in Jonathan Glenn's announcement
of appointment on 19 January 2016, the Company provides the
following updates.
Mr. Glenn's full name was disclosed as Jonathan M Glenn. Mr.
Glenn's full legal name is Jonathan Martin Glenn.
In addition to the current directorship of Consort Medical plc
("Consort Medical") that was disclosed at the time of his
appointment, Jonathan Glenn was also a director of a number of
subsidiaries of Consort Medical, as set out below:
AESICA BC Limited
AESICA Formulation Development Limited
AESICA Holdco Limited
AESICA M1 Limited
AESICA M2 Limited
AESICA Queensborough Limited
AESICA Trustee Company Limited
Bespak Europe Limited
Bespak Finance Limited
Bespak Holdings Limited
Consort Medical Finance 2010 Limited
Consort Medical Finance Limited
Consort Medical Limited
Integrated Aluminium Components Limited
Medical House (ASI) Limited
Medical House Products Limited
Pharmaron Manufacturing Services (UK) Ltd
The Medical House Group Limited
The Medical House Limited
Trevor Phillips
In addition to the directorship disclosures made in Trevor
Phillip's announcement of appointment on 5 January 2021, Trevor
Phillips had also held the following directorships within the
previous 5 years:
Vectura Group Limited (previously Vectura Group plc)
Vectura Limited
Vectura Delivery Devices Limited
Shervanthi Homer-Vanniasinkam
In addition to the disclosures made in Shervanthi
Homer-Vanniasinkam's announcement of appointment on 1 June 2016,
the following directorships are disclosed:
Directorship held at time of appointment to Tissue Regenix:
Holistx Limited
Directorship held within previous 5 years at time of appointment
to Tissue Regenix: The Vascular Society
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPFZGFMVMLGFZG
(END) Dow Jones Newswires
January 31, 2023 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2023 to Jun 2024